The term “senile chorea” was previously used to describe cases of insidious onset chorea in elderly patients who lacked family history of chorea. However, many of these patients have an identifiable etiology for their chorea. In this article, we discuss a case of generalized, insidious onset chorea in an 89-year-old man and apply a systematic diagnostic approach to chorea in the elderly to arrive at a diagnosis of late-onset Huntington’s disease. He is to our knowledge the second oldest case of late-onset Huntington’s disease reported in the literature and his case lends support to the expanding phenotype of Huntington’s disease.
PiccoloI, DefantiCA, SoliveriP, VolontèMA, CislaghiG, GirottiFCause and course in a series of patients with sporadic chorea. J Neurol2003;250(4):429–35.
2.
CherianA, ParamasivanNK, PuthanveeduDK, KrishnanS, NairARGeneralized chorea due to secondary polycythemia responding to phlebotomy. J Mov Disord2021;14(1):89–91.
3.
Lorincz MTGeriatric chorea. Clin Geriatr Med.2006;22(4):879–97. vii
4.
KolesnikM, BalloutAA, HameedN, NajjarSCase Report HSV-2 encephalitis presenting with chorea; effects of infection alone or combination of infection and autoimmunity? Front Neurol2021;12:790514.
5.
FeinsteinE, WalkerRTreatment of secondary chorea: A review of the current literature. Tremor Other Hyperkinet Mov (N Y)2020;10:22.
6.
OzbenS, ErolC, OzerF, TirasRChorea as the presenting feature of neurosyphilis. Neurol India2009;57(3):347–9.
7.
WarrenJD, FirgairaF, ThompsonEM, KneeboneCS, BlumbergsPC, ThompsonPDThe causes of sporadic and ‘senile’ chorea. Aust N Z J Med1998;28(4):429–31.
8.
GaigC, GrausF, ComptaY, HöglB, BatallerL, BrüggemannN, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology2017;88(18):1736–43.
9.
KyleK, BordelonY, VennaN, LinnoilaJAutoimmune and paraneoplastic chorea: A review of the literature. Front Neurol2022;13:829076.
10.
DubeyS, ChatterjeeS, GhoshR, LouisED, HazraA, SenguptaS, et al. Acute onset movement disorders in diabetes mellitus: A clinical series of 59 patients. Eur J Neurol2022;29(8):2241–8.
11.
OosterlooM, BijlsmaEK, van Kuijk SM, MinkelsF, de Die-Smulders CEClinical and genetic characteristics of late-onset Huntington’s disease. Parkinsonism Relat Disord2019;61:101–5.
12.
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: Gusella@helix.mgh.harvard.edu; Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell2019;178(4):887–900.e14.
13.
MaiuriT, SuartCE, HungCLK, GrahamKJ, Barba Bazan CA, TruantRDNA damage repair in Huntington’s disease and other neurodegenerative diseases. Neurotherapeutics2019;16(4):948–56.
14.
CorreiaK, HaroldD, KimKH, HolmansP, JonesL, OrthM, et al. The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide association analysis for genetic modifiers of Huntington’s disease. J Huntingtons Dis2015;4(3):279–84.
15.
TabriziSJ, SchobelS, GantmanEC, MansbachA, BorowskyB, KonstantinovaP, et al. A biological classification of Huntington’s disease: The Integrated Staging System. Lancet Neurol2022;21(7):632–44.
